199 related articles for article (PubMed ID: 30045961)
1. Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome.
Berridge G; Menassa DA; Moloney T; Waters PJ; Welding I; Thomsen S; Zuberi S; Fischer R; Aricescu AR; Pike M; Dale RC; Kessler B; Vincent A; Lim M; Irani SR; Lang B
Neurology; 2018 Aug; 91(8):e714-e723. PubMed ID: 30045961
[TBL] [Abstract][Full Text] [Related]
2. Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome.
Petit-Pedrol M; Guasp M; Armangue T; Lavarino C; Morales La Madrid A; Saiz A; Graus F; Dalmau J
Neurology; 2021 Feb; 96(7):e1082-e1087. PubMed ID: 33443132
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome.
Panzer JA; Anand R; Dalmau J; Lynch DR
J Neuroimmunol; 2015 Sep; 286():86-92. PubMed ID: 26298330
[TBL] [Abstract][Full Text] [Related]
4. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
5. Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.
Kumar P; Willard VW; Embry L; Naranjo A; LaBarre B; Matthay KK; de Alarcon PA
Pediatr Blood Cancer; 2024 Jul; 71(7):e31039. PubMed ID: 38689540
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma.
Rosenberg MI; Greenstein E; Buchkovich M; Peres A; Santoni-Rugiu E; Yang L; Mikl M; Vaksman Z; Gibbs DL; Reshef D; Salovin A; Irwin MS; Naranjo A; Ulitsky I; de Alarcon PA; Matthay KK; Weigman V; Yaari G; Panzer JA; Friedman N; Maris JM
Cell Rep; 2023 Aug; 42(8):112879. PubMed ID: 37537844
[TBL] [Abstract][Full Text] [Related]
7. Opsoclonus: clinical and immunological features.
Jen JC; Lopez I; Baloh RW
J Neurol Sci; 2012 Sep; 320(1-2):61-5. PubMed ID: 22818114
[TBL] [Abstract][Full Text] [Related]
8. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.
Connolly AM; Pestronk A; Mehta S; Pranzatelli MR; Noetzel MJ
J Pediatr; 1997 Jun; 130(6):878-84. PubMed ID: 9202608
[TBL] [Abstract][Full Text] [Related]
9. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Beck S; Fühlhuber V; Krasenbrink I; Tschernatsch M; Kneifel N; Kirsten A; Jaeger C; Kaps M; Preissner KT; Lang B; Rostasy K; Blaes F
J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
[TBL] [Abstract][Full Text] [Related]
10. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.
Petit-Pedrol M; Armangue T; Peng X; Bataller L; Cellucci T; Davis R; McCracken L; Martinez-Hernandez E; Mason WP; Kruer MC; Ritacco DG; Grisold W; Meaney BF; Alcalá C; Sillevis-Smitt P; Titulaer MJ; Balice-Gordon R; Graus F; Dalmau J
Lancet Neurol; 2014 Mar; 13(3):276-86. PubMed ID: 24462240
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting.
Anand S; Agarwala S; Jain V; Bakhshi S; Dhua A; Gulati S; Seth R; Srinivas M; Jana M; Kandasamy D; Bhatnagar V
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e924-e929. PubMed ID: 33769388
[TBL] [Abstract][Full Text] [Related]
12. Surgical considerations for neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: a series of 14 patients from a single institution.
Johnston WR; Hwang R; Mattei P
Pediatr Surg Int; 2022 Feb; 38(2):249-255. PubMed ID: 34549330
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
Blaes F; Pike MG; Lang B
J Neuroimmunol; 2008 Sep; 201-202():221-6. PubMed ID: 18687475
[TBL] [Abstract][Full Text] [Related]
14. Postinfectious SARS-CoV-2 Opsoclonus-Myoclonus-Ataxia Syndrome.
Nelson JL; Blume GM; Bansal SK; Kaufman JR; Woods FR; Zhang X; Kattah JC
J Neuroophthalmol; 2022 Jun; 42(2):251-255. PubMed ID: 34974489
[TBL] [Abstract][Full Text] [Related]
15. Glucose transporter type 1 deficiency syndrome associated with autoantibodies to glutamate receptors.
Hoshino H; Takayama K; Ishii A; Takahashi Y; Kanemura H
Brain Dev; 2020 Oct; 42(9):686-690. PubMed ID: 32591173
[TBL] [Abstract][Full Text] [Related]
16. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
Zar T; Tschernatsch M; Hero B; Lang B; Preissner KT; Blaes F
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e176-e179. PubMed ID: 33060390
[TBL] [Abstract][Full Text] [Related]
17. Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma.
Torres-Vega E; Durán-Moreno M; Sánchez Del Pino M; Yáñez Y; Cañete A; Castel V; López-Cuevas R; Vílchez JJ; Dalmau J; Graus F; García Verdugo JM; Bataller L
J Neuroimmunol; 2016 Aug; 297():98-102. PubMed ID: 27397082
[TBL] [Abstract][Full Text] [Related]
18. Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.
Patel A; Fischer C; Lin YC; Basu EM; Kushner BH; De Braganca K; Khakoo Y
Pediatr Blood Cancer; 2020 Aug; 67(8):e28319. PubMed ID: 32543116
[TBL] [Abstract][Full Text] [Related]
19. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.
Miske R; Scharf M; Borowski K; Rieckhoff N; Teegen B; Denno Y; Probst C; Guthke K; Didrihsone I; Wildemann B; Ruprecht K; Komorowski L; Jarius S
J Neuroinflammation; 2023 Mar; 20(1):88. PubMed ID: 36997937
[TBL] [Abstract][Full Text] [Related]
20. Opsoclonus-myoclonus-ataxia syndrome in children.
Bhatia P; Heim J; Cornejo P; Kane L; Santiago J; Kruer MC
J Neurol; 2022 Feb; 269(2):750-757. PubMed ID: 33779841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
